Tag Archives: SGLT2 inhibitors

The CKM framework in diabetes care—focusing on cardiovascular, kidney, and metabolic health—is more than a trend. It’s a clinical necessity. The ADA’s 2025 Standards of Care urge clinicians to manage these overlapping risks together, not separately. Why? Because patients with diabetes deserve outcomes that go beyond just A1C. This article …

Clinicians and care teams are increasingly focused on GLP‑1 receptor agonists, but SGLT2 inhibitors and metformin in diabetes management remain foundational in achieving comprehensive, evidence‑based outcomes. While GLP‑1 therapies generate headlines for weight loss and glucose control, 2025 guidelines still strongly emphasize the cardioprotective and renoprotective benefits of SGLT2 inhibitors …

Living with type 2 diabetes often means managing more than just blood glucose. For many patients, conditions like cardiovascular disease, chronic kidney disease, or depression take center stage in their care plan. When diabetes isn’t the main problem, how do you keep glucose control on track without compromising treatment for …